Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Minovia Therapeutics
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
September 18, 2025
From
Minovia Therapeutics
Via
GlobeNewswire
Tickers
LPAA
Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers
August 27, 2025
From
Minovia Therapeutics
Via
GlobeNewswire
Tickers
LPAA
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
April 03, 2025
From
Minovia Therapeutics
Via
GlobeNewswire
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
September 26, 2024
From
Minovia Therapeutics
Via
GlobeNewswire
Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member
January 05, 2023
From
Minovia Therapeutics
Via
GlobeNewswire
Minovia Therapeutics to Present at Biotech Showcase on Tuesday, January 10, 2023
January 03, 2023
From
Minovia Therapeutics
Via
GlobeNewswire
Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases
December 21, 2022
From
Minovia Therapeutics
Via
GlobeNewswire
Minovia Therapeutics Announces Data from Preclinical Studies Demonstrating that Mitochondrial Augmentation of CD34+ cells Confers Functional Benefit and that Mitochondrial Transfer Occurs Between Hematopoietic Cells In Vivo
October 01, 2021
From
Minovia Therapeutics
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.